Impact of pharmaceutical care in schizophrenic patients
- Conditions
- Health Condition 1: F209- Schizophrenia, unspecified
- Registration Number
- CTRI/2022/10/046427
- Lead Sponsor
- Dr Deepak C G
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Patient or caretaker
Patient or caretaker willing to provide informed consent
Patients aged � 18 and � 65 years old
Patients diagnosed with schizophrenia and schizophrenia spectrum disorders who were on the treatment of antipsychotic drugs with or without co-morbidities of hypertension, diabetes, hypercholesterolemia and weight gain
Both genders
Patient or caretaker unwilling to provide consent
Patients with other severe chronic medical conditions, including cancer, end-stage renal disease, heart failure and HIV
Patients with a diagnosis of Cushing syndrome, hypothyroidism, eating disorder
Patients who are engaged in the weight management programs within the past 3 months
Patients who are taking other forms of medicines to control weight including Ayurvedha, Homeopathy
Patients with co-existing physical illnesses that reduce their ability to participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Impact of pharmaceutical care in improvement or prevention cardiometabolic diseases in schizophrenia by controlling weight gain & obesity will be studiedTimepoint: 0 4 8 12 months
- Secondary Outcome Measures
Name Time Method Secondary outcomes: Measurement of medication adherence, quality of life and comparing the economic burden of schizophrenic patients by cost of illness studyTimepoint: 0 4 8 12 months